The Paroxysmal Nocturnal Hemoglobinuria treatment market is experiencing significant expansion, driven by increasing disease awareness, rising preval ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mereo Biopharma Group Plc (MREO – Research Report), Amgen (AMGN – Research Rep ...

The firm is hoping to show that the RNAi drug can treat HoFH by reducing production of ANGPTL3, which regulates lipid and lipoprotein metabolism.

ARO-C3 is an investigational RNA interference therapeutic designed to reduce liver production of complement component 3 as a potential therapy for various complement-mediated diseases.

The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

The placebo-controlled study is aimed at assessing the safety and efficacy of zodasiran in adults and adolescents with HoFH.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company’s investigational RNA interference ...

A 1‑for‑10 reverse stock split consolidates shares but not value. Learn how it works, why it's done, and see other recent ...

Emerging oligonucleotides and gene editing therapies offer greater precision, long-term efficacy, and improved adherence in comparison to traditional statin therapies. This is especially true for ...

Auxiliary Manufacturing continues full steam ahead, and is about to see its first production collaboration model through ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.